175250 — Icure Pharmaceutical Income Statement
0.000.00%
- KR₩90bn
- KR₩158bn
- KR₩57bn
- 25
- 25
- 70
- 31
Annual income statement for Icure Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 60,922 | 90,144 | 64,283 | 59,367 | 56,806 |
Cost of Revenue | |||||
Gross Profit | 18,210 | 18,097 | -4,659 | -5,580 | 1,298 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 67,301 | 100,648 | 96,692 | 87,511 | 81,702 |
Operating Profit | -6,379 | -10,504 | -32,409 | -28,144 | -24,895 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8,513 | -11,498 | -38,835 | -43,090 | -32,525 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8,654 | -12,150 | -38,384 | -42,549 | -32,299 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -8,751 | -12,614 | -38,167 | -41,766 | -31,420 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -8,751 | -12,614 | -38,167 | -41,766 | -31,420 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -412 | -664 | -1,423 | -1,753 | -799 |
Dividends per Share |